ARC and acute myeloid leukemia: AML patients with low or medium ARC expression exhibited longer overall survival (p = 0.0015) and longer remission duration (p = 0.000) compared with those with high ARC expression, indicating that ARC was an independent prognostic biomarker in AML treatment [75].